These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25855281)

  • 1. [The APJ receptor: a new therapeutic approach in diabetic treatment].
    Masri B; Dray C; Knauf C; Valet P; Castan-Laurell I
    Med Sci (Paris); 2015 Mar; 31(3):275-81. PubMed ID: 25855281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apelin/APJ system: A novel promising therapy target for pathological angiogenesis.
    Wu L; Chen L; Li L
    Clin Chim Acta; 2017 Mar; 466():78-84. PubMed ID: 28025030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis.
    O'Carroll AM; Lolait SJ; Harris LE; Pope GR
    J Endocrinol; 2013 Oct; 219(1):R13-35. PubMed ID: 23943882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apelin receptors: From signaling to antidiabetic strategy.
    Chaves-Almagro C; Castan-Laurell I; Dray C; Knauf C; Valet P; Masri B
    Eur J Pharmacol; 2015 Sep; 763(Pt B):149-59. PubMed ID: 26007641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apelin/APJ system and cancer.
    Yang Y; Lv SY; Ye W; Zhang L
    Clin Chim Acta; 2016 Jun; 457():112-6. PubMed ID: 27083318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apelin/APJ system as a therapeutic target in diabetes and its complications.
    Hu H; He L; Li L; Chen L
    Mol Genet Metab; 2016 Sep; 119(1-2):20-7. PubMed ID: 27650065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanding role for the apelin/APJ system in physiopathology.
    Carpéné C; Dray C; Attané C; Valet P; Portillo MP; Churruca I; Milagro FI; Castan-Laurell I
    J Physiol Biochem; 2007 Dec; 63(4):359-73. PubMed ID: 18457011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection of apelin and its signaling pathway.
    Cheng B; Chen J; Bai B; Xin Q
    Peptides; 2012 Sep; 37(1):171-3. PubMed ID: 22820556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apelin/APJ signaling system: a potential link between adipose tissue and endothelial angiogenic processes.
    Kunduzova O; Alet N; Delesque-Touchard N; Millet L; Castan-Laurell I; Muller C; Dray C; Schaeffer P; Herault JP; Savi P; Bono F; Valet P
    FASEB J; 2008 Dec; 22(12):4146-53. PubMed ID: 18708591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Apelin-APJ system: from discovery to therapeutic target].
    Kasai A
    Nihon Yakurigaku Zasshi; 2012 May; 139(5):198-202. PubMed ID: 22687871
    [No Abstract]   [Full Text] [Related]  

  • 11. Apelin/APJ signaling in hypoxia-related diseases.
    He L; Xu J; Chen L; Li L
    Clin Chim Acta; 2015 Dec; 451(Pt B):191-8. PubMed ID: 26436483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely.
    Sun X; Iida S; Yoshikawa A; Senbonmatsu R; Imanaka K; Maruyama K; Nishimura S; Inagami T; Senbonmatsu T
    Hypertens Res; 2011 Jun; 34(6):701-6. PubMed ID: 21412239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apelin/APJ System: A Novel Therapeutic Target for Myocardial Ischemia/Reperfusion Injury.
    Chen Z; Wu D; Li L; Chen L
    DNA Cell Biol; 2016 Dec; 35(12):766-775. PubMed ID: 27854125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural and functional study of the apelin-13 peptide, an endogenous ligand of the HIV-1 coreceptor, APJ.
    Fan X; Zhou N; Zhang X; Mukhtar M; Lu Z; Fang J; DuBois GC; Pomerantz RJ
    Biochemistry; 2003 Sep; 42(34):10163-8. PubMed ID: 12939143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apelin/APJ system as a therapeutic target in metabolic diseases.
    Castan-Laurell I; Masri B; Valet P
    Expert Opin Ther Targets; 2019 Mar; 23(3):215-225. PubMed ID: 30570369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis.
    Lv D; Li H; Chen L
    Acta Biochim Biophys Sin (Shanghai); 2013 Jul; 45(7):527-33. PubMed ID: 23588025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of the apelin-APJ axis in vascular formation.
    Kidoya H; Takakura N
    J Biochem; 2012 Aug; 152(2):125-31. PubMed ID: 22745157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic potentials of apelin in obesity-associated diseases.
    Castan-Laurell I; Dray C; Valet P
    Mol Cell Endocrinol; 2021 Jun; 529():111278. PubMed ID: 33838166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apelin: a novel neurohumoral modulator of the cardiovascular system. Pathophysiologic importance and potential use as a therapeutic target.
    Falcão-Pires I; Leite-Moreira AF
    Rev Port Cardiol; 2005 Oct; 24(10):1263-76. PubMed ID: 16398242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The apelin receptor: physiology, pathology, cell signalling, and ligand modulation of a peptide-activated class A GPCR.
    Chapman NA; Dupré DJ; Rainey JK
    Biochem Cell Biol; 2014 Dec; 92(6):431-40. PubMed ID: 25275559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.